Hepatitis B Surface Antigen shortage — CA supply status & alternatives

Hepatitis B Surface Antigen

—

🇦🇺 AUST R 123712 · GlaxoSmithKline Australia Pty Ltd

In supply · Australia

PreHevbri

In supply · 🇦🇺 Australia · short in🇨🇦 CA

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Hepatitis B Surface Antigen

Therapeutic category	Auto-created by EMA — Withdrawn / Refused / Revoked Medicines scraper

Controlled substance	No

Marketing-authorisation holders	GlaxoSmithKline Australia Pty Ltd

Registrations on file	2

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders2 registrations · 1 MA holder

Product	Strength	Form	Market	MA holder	Status
ENGERIX-B PAEDIATRIC DOSE hepatitis B surface antigen recombinant	10 microgram	—	🇦🇺 AU	GlaxoSmithKline Australia Pty Ltd	Active
ENGERIX-B hepatitis B surface antigen recombinant	20 microgram	—	🇦🇺 AU	GlaxoSmithKline Australia Pty Ltd	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.